文献速递胸部肿瘤

PALB2信使RNA表达与晚期非小细胞肺癌中铂类-多西他赛疗效的关联

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2018-11-22

该研究为BREC III期临床试验的预设次要分析,在177例接受顺铂-多西他赛治疗的非小细胞肺癌患者组织中检测PALB2等DNA修复基因mRNA水平。仅高PALB2 mRNA表达可预测无进展生存(HR=0.63,95%CI 0.42-0.83,p=0.0080)和总生存(HR=0.68,95%CI 0.42-0.90,p=0.0266),并在158例可评估疗效患者中与客观缓解率相关(高表达77% vs 低表达23%,p=0.0448)。作者认为高PALB2 mRNA表达可识别从顺铂-多西他赛化疗显著获益的患者。

要点

  • 在177例非小细胞肺癌患者中,仅高PALB2 mRNA表达可预测无进展生存(HR=0.63,95%CI 0.42-0.83,p=0.0080)。
  • 高PALB2 mRNA表达亦预测总生存(HR=0.68,95%CI 0.42-0.90,p=0.0266)。
  • 158例可评估疗效患者中,高PALB2 mRNA表达者客观缓解率77%,低表达者23%(p=0.0448)。

核心结论

  • 高PALB2 mRNA表达可识别在歐洲BREC III期临床试验中从顺铂-多西他赛化疗显著获益的非小细胞肺癌患者。
  • 作者指出化疗联合免疫治疗将成为标准治疗,化疗疗效预测标志物可能准确指导治疗决策。

研究设计与样本

  • 本研究为BREC III期临床试验(ClinicalTrials.gov标识NCT00617656)的预设次要目标。
  • 在177例接受顺铂-多西他赛治疗的非小细胞肺癌患者组织中评估PALB2及RNF8、RIF1、ATM、53BP1四种DNA修复基因的mRNA水平。
  • 分析基因表达水平与无进展生存、总生存及缓解的关系。

主要发现

  • 177例患者中位年龄62岁,包括140例男性和91例腺癌患者。
  • 仅高PALB2 mRNA表达在无进展生存Cox回归分析中具有预测性(HR=0.63,95%CI 0.42-0.83,p=0.0080)。
  • PALB2亦预测总生存(HR=0.68,95%CI 0.42-0.90,p=0.0266)。
  • 158例可评估疗效患者中,高PALB2 mRNA表达者客观缓解率77%,低表达者仅23%(p=0.0448)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Partner and localizer of BRCA2 (PALB2) is essential for homologous recombination repair. We examined mRNA levels of DNA repair genes, including partner and localizer of BRCA2 gene (PALB2), ring finger protein 8 gene (RNF8), replication timing regulatory factor 1 gene (RIF1), ATM serine/threonine kinase gene (ATM), and tumor protein p53 binding protein 1 gene (53BP1) as predictive biomarkers for cisplatin-docetaxel in the European phase III BRCA1, DNA repair associated (BRCA1)-receptor-associated protein 80 (RAP80) expression customization (BREC) phase III clinical trial (ClinicalTrials.gov identifier NCT00617656). METHODS: The study was a prespecified secondary objective of the BREC trial. We assessed mRNA levels of PALB2 and four more DNA repair genes (RNF8, RIF1, ATM and 53BP1) as biomarkers in tissue from 177 patients with cisplatin-docetaxel-treated NSCLC. We examined the relationship of gene expression levels with progression-free survival, overall survival, and response. RESULTS: In 177 patients with NSCLC (who had a median age of 62 years and included 140 men and 91 patients with adenocarcinoma), only high PALB2 mRNA expression was predictive in the progression-free survival Cox regression analysis (hazard ratio = 0.63, 95% confidence interval: 0.42-0.83, p = 0.0080). PALB2 was also predictive of overall survival (hazard ratio = 0.68, 95% confidence interval: 0.42-0.90, p = 0.0266). Among the 158 patients evaluable for response, high PALB2 mRNA expression was predictive of response to cisplatin-docetaxel. Specifically, an objective response rate of 77% to cisplatin-docetaxel was observed for patients with high PALB2 mRNA expression compared with a rate of only 23 % for those with low PALB2 mRNA expression (p = 0.0448). CONCLUSIONS: High PALB2 mRNA expression identified patients with NSCLC who significantly benefited from cisplatin-docetaxel chemotherapy in the European BREC phase III clinical trial. The combination of chemotherapy with immunotherapy will become the standard of care, and a predictive marker of response to chemotherapy may accurately guide therapeutic decision making.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Karachaliou N, Bracht JWP, Fernandez Bruno M, et al. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 30472259. doi:10.1016/j.jtho.2018.10.168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。